ARYX Stock Overview

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. More details

ARYX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($33)

My Notes

Capture your thoughts, links and company narrative

ARYx Therapeutics, Inc. Competitors

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

MJ Holdings

OTCPK:MJNE

US$58.0

Juva Life

OTCPK:JUVA.F

US$164.0

Price History & Performance

Summary of share price highs, lows and changes for ARYx Therapeutics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.000001
52 Week Low	US$0.000001
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-99.95%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	ARYX	US Pharmaceuticals	US Market
7D	0%	-0.6%	-0.2%
1Y	n/a	3.0%	25.8%

Return vs Industry: Insufficient data to determine how ARYX performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ARYX performed against the US Market.

Price Volatility

Is ARYX's price volatile compared to industry and market?
ARYX volatility
ARYX Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.8%
Market Average Movement	6.4%
10% most volatile stocks in US Market	18.6%
10% least volatile stocks in US Market	3.1%

Stable Share Price: ARYX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine ARYX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1997	n/a	n/a	n/a

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat.

ARYx Therapeutics, Inc. Fundamentals Summary

How do ARYx Therapeutics's earnings and revenue compare to its market cap?
ARYX fundamental statistics
Market cap	US$33.00
Earnings (TTM)	-US$18.33m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is ARYX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARYX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$18.33m
Earnings	-US$18.33m

Last Reported Earnings

Sep 30, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did ARYX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 05:26
End of Day Share Price	2024/12/23 00:00
Earnings	2010/09/30
Annual Earnings	2009/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ARYx Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Marko Kozul	Jefferies LLC
Bret Holley	Oppenheimer & Co. Inc.
Duane Nash	Wedbush Securities Inc.